Company: DHR
Filing Date: 2025-02-20
Form Type: 10-K
Source: 0000313616-25-000043
Chunk: 288

Company: DANAHER CORP /DE/
Filing Date: 2025-02-20
Form: 10-K
Item: Item 7
Chunk 288
---
577 $10,849 Operating profit2,625 2,406 3,436 Depreciation 394 379 387 Amortization of intangible assets192 198 203 Operating profit as a % of sales26.8 %25.1 %31.7 %Depreciation as a % of sales4.0 %4.0 %3.6 %Amortization as a % of sales2.0 %2.1 %1.9 %

Sales Growth (Decline) and Core Sales Growth (Decline)

2024 vs. 20232023 vs. 2022Total sales growth (decline) (GAAP)2.0 %(11.5)%Impact of:Currency exchange rates 1.0 %1.0 %Core sales growth (decline) (non-GAAP)3.0 %(10.5)%

2024 Sales Compared to 2023 

Price increases in the segment did not have a significant impact on sales growth on a year-over-year basis during 2024 as compared with 2023.

During 2024, total segment sales increased 2.0% primarily as a result of increased core sales resulting from the factors discussed below.  Changes in currency exchange rates negatively impacted sales year-over-year.  Overall segment core sales growth was driven primarily by North America, partially offset by lower year-over-year demand in high-growth markets.  During the year, core sales in the molecular diagnostics business grew on a year-over-year basis primarily driven by increased sales of both respiratory and non-respiratory disease tests in North America.  In the segment’s clinical diagnostics businesses, core sales grew on a year-over-year basis led by the clinical lab business, and to a lesser extent by the pathology and acute care businesses.  The increased core sales in the clinical diagnostics businesses were driven by core sales growth in developed markets.  

40

Operating Profit Performance

Operating profit margins increased 170 basis points during 2024 as compared to 2023.  The following factors impacted year-over-year operating profit margin comparisons.       

2024 vs. 2023 operating profit margin comparisons were favorably impacted by:

•Higher 2024 core sales, improvements in the segment’s operational and administrative cost structure and the impact of product mix - 250 basis points

2024 vs. 2023 operating profit margin comparisons were unfavorably impacted by:

•2024 loss on